As dasatinib leads to synthetic lethality in ovarian clear cell tumours with an ARID1A (AT‐rich interactive domain 1A) mutation 37, our finding expands the application range of dasatinib for ovarian cancers. Here, ARID1A is linked to ovarian carcinoma.